Immunotherapy prospects for acute myeloid leukaemia

Clinical and Experimental Immunology

Volumn 161, Issue 2, 2010, Pages 223-232

  Barrett, A J ^a   Le Blanc, K ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AML; antibodies; cell therapy; vaccines

Indexed keywords

ANTIBODY; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; GEMTUZUMAB OZOGAMICIN; IMMUNOMODULATING AGENT; PEPTIDE VACCINE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CELL LYSATE; DENDRITIC CELL; HUMAN; IMMUNOSURVEILLANCE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER INJURY; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE;

EID: 77954635822     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04197.x     Document Type: Review

References (108)

1. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Semin Hematol 1987 24 : 40 54.
2. Powles RL, Russell J, Lister TA et al. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer 1977 35 : 265 72.
3. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008 142 : 877 88.
4. Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol 2003 120 : 442 51.
5. Berke G. The CTL's kiss of death. Cell 1995 81 : 9 12.
6. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003 90 : 127 56.
7. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999 96 : 8639 44.
8. Distler E, Wölfel C, Köhler S et al. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. Exp Hematol 2008 3 : 451 63.
9. Norde WJ, Overes IM, Maas F et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood 2009 113 : 2312 23.
10. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009 21 : 525 30.
11. Cooley S, Trachtenberg E, Bergemann TL et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009 11 : 726 32.
12. Savani BN, Mielke S, Adams S et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007 21 : 2145 52.
13. Pattengale PK, Sundstrom C, Yu AL, Levine A. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells. Nat Immun Cell Growth Regul 1983-1984 3 : 165 80.
14. Lowdell MW, Ray N, Craston R, Corbett T, Deane M, Prentice HG. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant 1997 19 : 891 7.
15. Verheyden S, Ferrone S, Mulder A et al. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother 2009 58 : 855 65.
16. Yan WH, Lin A, Chen BG et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008 12 : 889 98.
17. Zhong RK, Lane TA, Ball ED. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. Exp Hematol 2008 36 : 486 94.
18. Draube A, Beyer M, Wolf J. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur J Haematol 2008 81 : 281 8.
19. Rezvani K, Yong AS, Tawab A et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009 113 : 2245 55.
20. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 2007 148 : 189 98.
21. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994 367 : 645 8.
22. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004 5 : 738 43.
23. Bruserud O, Ulvestad E, Berentsen S, Bergheim J, Nesthus I. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation. Scand J Immunol 1998 47 : 54 62. (Pubitemid 28057352)
24. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008 112 : 407 15.
25. Behl D, Porrata LF, Markovic SN et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006 20 : 29 34.
26. Barrett AJ, Savani BN. Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia 2009 23 : 53 8.
27. Ohnishi K, Yamanishi H, Naito K et al. Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia. Leukemia 1998 12 : 52 8.
28. Pérez-García A, Brunet S, Berlanga JJ et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 2009 23 : 486 91.
29. Verheyden S, Bernier M, Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004 18 : 2002 7.
30. Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997 19 : 989 99.
31. Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009 361 : 478 88.
32. Baessler T, Krusch M, Schmiedel BJ et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009 69 : 1037 45.
33. Scholl N, Loibl J, Kremser A et al. The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. Leuk Lymph 2009 50 : 427 36.
34. van Luijn MM, Chamuleau ME, Thompson JA et al. CLIP down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T cell responses. Haematologica 2010 95 : 485 93.
35. Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function - implications for the adoptive immunotherapy of leukaemia. Cancer 1979 44 : 1298 304.
36. Panoskaltsis N, Reid CD, Knight SC. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia 2003 17 : 716 30.
37. Tong XM, Yao HP, Qian WB et al. The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells. Int J Lab Hematol 2008 30 : 372 81.
38. Schui DK, Singh L, Schneider B, Knau A, Hoelzer D, Weidmann E. Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts. Leuk Res 2002 26 : 383 9.
39. Mohty M, Jarrossay D, Lafage-Pochitaloff M et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001 98 : 3750 6.
40. Narita M, Takahashi M, Liu A et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol 2001 29 : 709 19.
41. Ge W, Ma X, Li X et al. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leuk Res 2009 33 : 948 57.
42. Wang X, Zheng J, Liu J et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005 75 : 468 76.
43. Li Y, Yin Q, Yang L et al. Reduced levels of recent thymic emigrants in acute myeloid leukemia patients. Cancer Immunol Immunother 2009 58 : 1047 55.
44. Le Dieu R, Taussig DC, Ramsay AG et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009 114 : 3909 16.
45. Zhi-Gang Z, Wei-Ming L, Zhi-Chao C, Yong Y, Ping Z. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leuk Lymph 2008 49 : 2187 95.
46. Lapidot T, Goichberg P, Lapid K, Avigdor A, Kollet O. The endosteum region keeps human leukemic stem cells alive. Cell Stem Cell 2007 1 : 483 4.
47. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 2006 8 : 554 8.
48. Dunussi-Joannopoulos K. The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma. Leuk Lymph 2002 43 : 2075 82.
49. Zhou Q, Bucher C, Munger ME et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009 114 : 3793 802.
50. Sanchez PV, Perry RL, Sarry JE et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009 23 : 2109 17.
51. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006 12 : 1167 74.
52. Stauss HJ, Thomas S, Cesco-Gaspere M et al. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008 40 : 113 6.
53. Agliano A, Martin-Padura I, Mancuso P et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008 123 : 2222 7.
54. Macdonald D, Jiang YZ, Gordon AA et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk Res 1990 14 : 967 73.
55. Lotzová E, Savary CA, Schachner JR, Huh JO, McCredie K. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2. Am J Hematol 1991 37 : 88 99.
56. Sievers EL, Lange BJ, Sondel PM et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998 16 : 914 9.
57. Meloni G, Foa R, Vignetti M et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994 84 : 2158 63.
58. Stone RM, DeAngelo DJ, Janosova A et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol 2008 83 : 771 7.
59. Baer MR, George SL, Caligiuri MA et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and Leukemia Group B Study 9720. J Clin Oncol 2008 26 : 4934 9.
60. Macdonald D, Jiang YZ, Swirsky D et al. Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Br J Haematol 1991 77 : 43 9.
61. Romero AI, Thorén FB, Aurelius J, Askarieh G, Brune M, Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009 70 : 194 205.
62. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 2010 59 : 73 9.
63. Hicks C, Keoshkerian E, Gaudry L, Lindeman R. CD80 (B7-1) expression on human acute myeloid leukaemic cells cultured with GM-CSF, IL-3 and IL-6. Cancer Immunol Immunother 2001 50 : 173 80.
64. Borrello IM, Levitsky HI, Stock W et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009 114 : 1736 45.
65. Stein C, Kellner C, Kugler M et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 2010 148 : 879 89.
66. Seiffert M, Cant C, Chen Z et al. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 1999 94 : 3633 43.
67. Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. 2009 138 : 286 99.
68. Zhao X, Singh S, Pardoux C et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95 : 71 8.
69. Stahnke B, Thepen T, Stocker M et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008 7 : 2924 32.
70. Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986 68 : 1030 5.
71. Larson RA, Sievers EL, Stadtmauer EA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005 104 : 1442 52.
72. Amadori S, Suciu S, Stasi R et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005 19 : 1768 73.
73. Estey EH, Thall PF, Giles FJ et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002 99 : 4343 9.
74. Tsimberidou A, Estey E, Cortes J et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003 97 : 1481 7.
75. Clavio M, Vignolo L, Albarello A et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007 138 : 186 95.
76. Fianchi L, Pagano L, Leoni F et al. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol 2008 19 : 128 34.
77. Chevallier P, Delaunay J, Turlure P et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008 26 : 5192 7.
78. Kobayashi Y, Tobinai K, Takeshita A et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol 2009 89 : 460 9.
79. Mulford D. Antibody therapy for acute myeloid leukemia. Semin Hematol 2008 45 : 104 9.
80. Cheuk AT, Guinn BA. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine. Front Biosci 2008 13 : 2022 9.
81. Ingram W, Kordasti S, Chan L et al. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures. Cancer Immunol Immunother 2009 58 : 1679 90.
82. Roddie H, Klammer M, Thomas C et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Brit J Haematol 2006 133 : 152 7.
83. Lei Z, Zhang GM, Hong M, Feng ZH, Huang B. Fusion of dendritic cells and CD34+CD38- acute myeloid leukemia (AML) cells potentiates targeting AML-initiating cells by specific CTL induction. J Immunother 2009 32 : 408 14.
84. Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist 2009 14 : 240 52.
85. Van Driessche A, Van de Velde AL, Nijs G et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009 11 : 653 68.
86. Duncan C, Roddie H. Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol 2008 21 : 521 41.
87. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukaemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006 91 : 1653 61.
88. Schmitt M, Casalegno-Garduño R, Xu X, Schmitt A. Peptide vaccines for patients with acute myeloid leukemia. Exp Rev Vaccines 2009 8 : 1415 25.
89. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004 101 : 13885 90.
90. Keilholz U, Letsch A, Busse A et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009 113 : 6541 8.
91. Qazilbash MH, Wieder E, Thall PF, Molldrem J. PR1 peptide vaccine induced immune response is associated with better event-free survival in patients with myloid leukemia. Blood 2007 101 : Suppl. 1 Abstract 283.
92. Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008 111 : 236 42.
93. Greiner J, Schmitt A, Giannopoulos K et al. High dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). Haematologica 2010 E-Pub.
94. Meyer-Monard S, Passweg J, Siegler U et al. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. Transfusion 2009 49 : 362 71.
95. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005 105 : 3051 7.
96. Berg M, Lundqvist A, McCoy P et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009 11 : 341 55.
97. Fujisaki H, Kakuda H, Shimasaki N et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009 69 : 4010 7.
98. Medina DJ, Gharibo M, Savage P et al. A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leuk Res 2008 32 : 1842 8.
99. Colvin GA, Berz D, Ramanathan M et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 2009 15 : 421 31.
100. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010 184 : 1885 96.
101. Vera JF, Brenner MK, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther 2009 9 : 396 408.
102. Delluc S, Hachem P, Rusakiewicz S et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother 2009 58 : 1669 77.
103. Ruter J, Barnett BG, Kryczek I et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009 14 : 1761 70.
104. Natsume A, Wakabayashi T, Tsujimura K et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008 122 : 2542 53.
105. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009 23 : 641 8.
106. Smits EL, Cools N, Lion E et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother 2010 59 : 35 46.
107. Yong AS, Keyvanfar K, Hensel N et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009 113 : 875 82.
108. Barrett J, Rezvani K. Immunotherapy: can we include vaccines with stem-cell transplantation? Nat Rev Clin Oncol 2009 6 : 503 5.